2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).
The concordance of mutational status between primary tumor and metastases in CRC is typically between 80 to 95%, says Fedyanin. But in his study they identified a high discordance status. This is connected to the time between primary tumor resection and metastasectomy, which is about 1 year.
Other studies investigating this same area also found mutation discordance in KRAS, NRAS, BRAF and other genes.
Related Content: